GH1 and bone neoplasm: Our study shows a 3.5‐3.8‐fold higher incidence of and a 5‐fold higher mortality from bone tumors in patients treated with GH for idiopathic isolated GH deficiency, idiopathic short stature, or short stature in children born short for gestational age, than in the general population.